Biology of Blood and Marrow Transplantation
Volume 9, Issue 10 , Pages 616-632 , October 2003

Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects

  • Cynthia R Giver

      Affiliations

    • Winship Cancer Institute, Hematology/Oncology Department, Emory University, Atlanta, Georgia, USA
    • ,
  • Richard O Montes

      Affiliations

    • Winship Cancer Institute, Hematology/Oncology Department, Emory University, Atlanta, Georgia, USA
    • ,
  • Stephen Mittelstaedt

      Affiliations

    • Winship Cancer Institute, Hematology/Oncology Department, Emory University, Atlanta, Georgia, USA
    • ,
  • Jian-Ming Li

      Affiliations

    • Winship Cancer Institute, Hematology/Oncology Department, Emory University, Atlanta, Georgia, USA
    • ,
  • David L Jaye

      Affiliations

    • Department of Pathology, Emory University, Atlanta, Georgia, USA
    • ,
  • Sagar Lonial

      Affiliations

    • Winship Cancer Institute, Hematology/Oncology Department, Emory University, Atlanta, Georgia, USA
    • ,
  • Michael W Boyer

      Affiliations

    • Columbus Children’s Hospital, Columbus, Ohio, USA
    • ,
  • Edmund K Waller

      Affiliations

    • Corresponding Author InformationCorrespondence and reprint requests: Edmund K. Waller, MD, PhD, Emory University, Department of Hematology/Oncology, 1639 Pierce Dr., Ste. 1003, Atlanta, GA 30322, USA
    • Winship Cancer Institute, Hematology/Oncology Department, Emory University, Atlanta, Georgia, USA

Received 22 October 2002 ,Accepted 26 June 2003.

References 

  1. Waller EK, Ship AM, Mittelstaedt S, et al.  Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. Blood. 1999;94:3222–3233
  2. Waller EK, Boyer M. New strategies in allogeneic stem cell transplantation (immunotherapy using irradiated allogeneic T cells). Bone Marrow Transplant. 2000;(suppl 2):S20–S24
  3. Roux E, Abdi K, Speiser D, et al.  Characterization of mixed chimerism in patients with chronic myeloid leukemia transplanted with T-cell—depleted bone marrow (involvement of different hematologic lineages before and after relapse). Blood. 1993;81:243–248
  4. Avramis VI, Plunkett W. 2-fluoro-ATP (a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine). Biochem Biophys Res Commun. 1983;113:35–43
  5. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem. 1990;265:16617–16625
  6. Priebe T, Platsoucas CD, Seki H, Fox FE, Nelson JA. Purine nucleoside modulation of functions of human lymphocytes. Cell Immunol. 1990;129:321–328
  7. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995;13:2431–2448
  8. Sandoval A, Consoli U, Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res. 1996;2:1731–1741
  9. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999;5:444–447
  10. Sha WC, Nelson CA, Newberry RD, Kranz DM, Russell JH, Loh DY. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature. 1988;335:271–274
  11. Cooke KR, Hill GR, Crawford JM, et al.  Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102:1882–1891
  12. Gillis S, Mizel SB. T-cell lymphoma model for the analysis of interleukin 1-mediated T-cell activation. Proc Natl Acad Sci U S A. 1981;78:1133–1137
  13. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol. 1981;126:1614–1619
  14. Lyons AB. Divided we stand (tracking cell proliferation with carboxyfluorescein diacetate succinimidyl ester). Immunol Cell Biol. 1999;77:509–515
  15. Cox DR, Oakes D. Proportional hazards model. In:  Cox DR,  Oakes D editor. Analysis of Survival Data. New York: Chapman and Hall; 1984;p. 104–106
  16. Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant. 1995;16:289–295
  17. Bittencourt MC, Perruche S, Contassot E, et al.  Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers. Blood. 2001;98:224–230
  18. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo (new answers to an old question). J Immunol. 2001;166:973–981
  19. Maury S, Salomon B, Klatzmann D, Cohen JL. Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice. Blood. 2001;98:3156–3158
  20. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493–3499
  21. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98:3192–3204
  22. Bordignon C, Bonini C, Verzeletti S, et al.  Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther. 1995;6:813–819
  23. Bonini C, Bordignon C. Potential and limitations of HSV-TK-transduced donor peripheral blood lymphocytes after allo-BMT. Hematol Cell Ther. 1997;39:273–274
  24. Bonini C, Ferrari G, Verzeletti S, et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719–1724
  25. van Dijk AM, Kessler FL, Stadhouders-Keet SA, Verdonck LF, de Gast GC, Otten HG. Selective depletion of major and minor histocompatibility antigen reactive T cells (towards prevention of acute graft-versus-host disease). Br J Haematol. 1999;107:169–175
  26. Guinan EC, Boussiotis VA, Neuberg D, et al.  Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340:1704–1714
  27. Taylor PA, Panoskaltsis-Mortari A, Noelle RJ, Blazar BR. Analysis of the requirements for the induction of CD4+ T cell alloantigen hyporesponsiveness by ex vivo anti-CD40 ligand antibody. J Immunol. 2000;164:612–622
  28. Drobyski WR, Majewski D, Ozker K, Hanson G. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. J Immunol. 1998;161:2610–2619
  29. Bachar-Lustig E, Reich-Zeliger S, Gur H, Zhao Y, Krauthgamer R, Reisner Y. Bone marrow transplantation across major genetic barriers (the role of megadose stem cells and nonalloreactive donor anti-third party CTLS). Transplant Proc. 2001;33:2099–2100
  30. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood. 2002;99:3083–3088
  31. Grass JA, Wafa T, Reames A, et al.  Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood. 1999;93:3140–3147
  32. Truitt R, Johnson B, Hanke C, Talib S, Hearst J. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol. 1999;163:5145–5156
  33. Hsieh MH, Varadi G, Flomenberg N, Korngold R. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk. Biol Blood Marrow Transplant. 2002;8:303–315
  34. Ship AM, Waller EK. Clinical use of irradiated donor lymphocytes in bone marrow transplantation. Cancer Treat Res. 1999;101:267–282
  35. Aguado E, Richelme S, Nunez-Cruz S, et al.  Induction of T helper type 2 immunity by a point mutation in the LAT adaptor. Science. 2002;296:2036–2040
  36. Coudert JD, Foucras G, Demur C, et al.  Lethal host-versus-graft disease and hypereosinophilia in the absence of MHC I-T-cell interactions. J Clin Invest. 2000;105:1125–1132
  37. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection (considerations for the allogeneic transplantation therapy of leukemia and lymphoma). Leuk Lymphoma. 2000;38:221–234
  38. Boumpas DT, Tassiulas IO, Fleisher TA, et al.  A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin Nephrol. 1999;52:67–75
  39. Kishimoto H, Sprent J. Strong TCR ligation without costimulation causes rapid onset of Fas-dependent apoptosis of naive murine CD4+ T cells. J Immunol. 1999;163:1817–1826
  40. Desbarats J, Wade T, Wade WF, Newell MK. Dichotomy between naive and memory CD4(+) T cell responses to Fas engagement. Proc Natl Acad Sci U S A. 1999;96:8104–8109
  41. Hartwig UF, Robbers M, Wickenhauser C, Huber C. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood. 2002;99:3041–3049
  42. Villunger A, Egle A, Kos M, et al.  Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 1997;57:3331–3334
  43. Jones DT, Ganeshaguru K, Virchis AE, et al.  Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood. 2001;98:2800–2807
  44. Snider D, Liang H. Early intestinal Th1 inflammation and mucosal T cell recruitment during acute graft-versus-host reaction. J Immunol. 2001;166:5991–5999
  45. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med. 2000;192:549–556
  46. Cooke KR, Gerbitz A, Crawford JM, et al.  LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107:1581–1589
  47. Clouthier SG, Ferrara JL, Teshima T. Graft-versus-host disease in the absence of the spleen after allogeneic bone marrow transplantation. Transplantation. 2002;73:1679–1681
  48. Anderson BE, McNiff J, Yan J, et al.  Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112:101–108
  49. Chen B, Cui J, Chao NJ. Differential effects of naive and non-naive T-cells on GvHD (implications in separating GvL from GvHD). Blood. 2002;100:70a; (abstr.)

PII: S1083-8791(03)00229-5

doi: 10.1016/S1083-8791(03)00229-5

Biology of Blood and Marrow Transplantation
Volume 9, Issue 10 , Pages 616-632 , October 2003

Article Tools

* Image Usage & Resolution